(Press-News.org) Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease. In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in PD patients. PD patients were divided into two groups: 20 patients received Exenatide injections for 12 months, while the other group of 24 patients served as controls. Due to high manufacturing costs, the control group did not receive placebo injections and the patients were aware of their group assignment. Foltynie and colleagues observed that Exenatide was well tolerated. After one year of treatment patients receiving Exenatide displayed improved cognitive ability and motor skills, while control patients declined. Though this trial cannot rule out a placebo effect, the study suggests that Exenatide may improved motor function in PD patients and provides a strong rationale for conducting a larger, blinded study to determine the effectiveness of Exenatide in PD. In the accompanying commentary, Roger Barker (University of Cambridge), Mark Stacy (Duke University) and Patrik Brundin (Van Andel Institute) discuss the novel, cost-saving clinical trial design used in this study.
###
This study was funded by Cure Parkinson's Trust. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
TITLE:
Exenatide and the treatment of patients with Parkinson's disease
AUTHOR CONTACT:
Thomas Foltynie
UCL Institute of Neurology, London, GBR
Phone: 44 203 448 8726; E-mail: T.Foltynie@ucl.ac.uk
View this article at: http://www.jci.org/articles/view/68295?key=424690bda975bb0c7d68
ACCOMPANYING COMMENTARY
TITLE:
A new approach to disease-modifying drug trials in Parkinson's disease
AUTHOR CONTACT:
Patrik Brundin
Van Andel Institute, Grand Rapids, MI, USA
Phone: 616-234-5684; E-mail: Patrik.Brundin@vai.org
View this article at: http://www.jci.org/articles/view/69690?key=5b7b3c4b320e2bc2a0e5 END
Diabetes drug tested in Parkinson's disease patients
2013-05-20
ELSE PRESS RELEASES FROM THIS DATE:
Women with severe injuries are less likely than men to be treated in a trauma center
2013-05-20
ATS 2013, PHILADELPHIA - Women are less likely than men to receive care in a trauma center after severe injury, according to a new study of almost 100,000 Canadian patients.
"Gender-based disparities in access to healthcare services in general have been recognized for some time and evidence is emerging that these disparities extend to the treatment of severe injuries in trauma centers," says lead author Andrea Hill. MSc, PhD, a post-doctoral fellow at Sunnybrook Health Sciences Centre and the University of Toronto in Ontario, Canada. "Our study confirms and expands on ...
Source of infection affects hospital mortality in septic shock patients in the ICU
2013-05-20
In ICU patients who have septic shock, the anatomic source of infection has a strong effect on the chances of survival, according to a new study from researchers in Canada.
"Understanding the local infection source in patients with septic shock may influence treatment strategies and clinical outcomes," said researcher Peter Dodek, MD MHSc, professor of critical care medicine at the University of British Columbia in Vancouver. "Accordingly, we examined the relationship between anatomic source of infection and hospital mortality in nearly 8,000 patients who had septic ...
New study identifies risk factors for depression among COPD patients
2013-05-20
ATS 2013, PHILADELPHIA ─ Patients suffering from chronic obstructive pulmonary disease (COPD) typically suffer from depression more frequently than those without COPD, resulting in higher levels of disability and illness and increasing the overall healthcare burden for the COPD population. Now, a study from researchers in Argentina indicates female COPD patients and patients who experience significant shortness of breath may have the greatest risk for developing depression.
The results of the study will be presented at the ATS 2013 International Conference.
"About ...
Stress test may help predict increased mortality risk in sleep apnea patients
2013-05-20
ATS 2013, PHILADELPHIA – Many studies have shown that men and women who suffer from obstructive sleep apnea (OSA) - a disorder that causes breathing to halt intermittently during sleep – have a higher mortality rate than those who do not have the disorder. Now, a study from researchers at the Cleveland Clinic shows that OSA patients who also have poor functional capacity have an even greater risk of mortality and suggests that an assessment of functional capacity in this population can help physicians identify patients most at risk for death.
The results of the study ...
Metabolic biomarkers can predict mortality in the ICU
2013-05-20
ATS 2013, PHILADELPHIA – A metabolic profile of intensive care unit (ICU) patients based on biomarkers of four metabolites can be used to accurately predict mortality, according to a new study.
"Existing models for predicting mortality in the ICU may not always be accurate and they can also be cumbersome to use," said researcher Angela J. Rogers MD, MPH, Instructor in Medicine at Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School in Boston. "Levels of lactate, a metabolite from the carbohydrate pathway, are an established biomarker for ICU mortality. ...
Food laboratory accuracy remains a concern
2013-05-20
Food microbiology laboratories continue to submit false negative results and false positive results on a routine basis. A retrospective study of nearly 40,000 proficiency test results over the past 14 years, presented today at the 113th General Meeting of the American Society for Microbiology, examined the ability of food laboratories to detect or rule out the presence of Escherichia coli O157:H7, Salmonella, Listeria monocytogenes, and Campylobacter.
"There is concern when laboratories report that pathogens are not found in a food sample, when in fact they are there," ...
Pharmaceutical advances offer new options for health outcomes
2013-05-20
Orlando, FL (May 20, 2013) — Research presented at Digestive Disease Week® (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C.
An international study holds promising results for patients suffering from IBS-D. In the phase II study, researchers found that the drug ibodutant significantly improved symptoms in more than 50 percent of the individuals treated.
"While there's been a lot of progress in medicines for IBS with constipation, we haven't seen the same in IBS with diarrhea," said Jan Tack, MD, professor ...
Mayo Clinic: Inflammatory bowel disease raises risk of melanoma
2013-05-20
ROCHESTER, Minn. — Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. The findings were presented at the Digestive Disease Week 2013 conference in Orlando, Fla.
More than 1.5 million Americans have Crohn's disease or ulcerative colitis (UC), the most common forms of inflammatory bowel disease. Both conditions inflame the lining of the intestine, leading to bouts of watery diarrhea, rectal bleeding, ...
Team finds mechanism linking key inflammatory marker to cancer
2013-05-20
CHAMPAIGN, Ill. — In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.
Scientists call this Jekyll-and-Hyde molecule NF-kappa B. In healthy cells, it is a powerful "first responder," a vital part of the body's immune and inflammatory responses. It spends most of its life in the cell's cytoplasm, quietly awaiting orders. But when extracellular signals – of a viral or bacterial invasion, for example – set off chemical alarms, ...
New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More
2013-05-20
Boulder, Colo., USA – New Geology articles posted online ahead of print 9 and 16 May 2013 cover a wide swath of geoscience subdisciplines, including minerals exploration, archaeology, planetary geology, tectonics, oceanography, geophysics, and paleobotany. Locations studied include Siberia; the Sumatran subduction margin; the Monte Arsiccio mine at Alpi Apuane, Italy; Ukraine; Mars; and the Southeastern U.S. Atlantic Margin. Brief highlights follow:
1. Rubies, jadeite, and plate tectonics;
2. The clear fingerprint of ice ages left on coral reefs around the world;
3. ...